EU progress on human tissue products regulation stalls again
This article was originally published in Clinica
The European Commission is delaying again publication of the first draft of the EU's Human Tissue Engineered Products (HTEP) Regulation. The results of further investigations into how research in hospitals into HTEPs would be affected by the current version of the proposed document has persuaded the Commission to carry out further changes.
You may also be interested in...
Discussions on the shape of health care have moved from “reimagining” to the next stage: building and executing on the vision. That is the thrust of EY’s NextWave Report: New Horizons 2019. Additionally, for medtechs seeking business continuum, “duality” is now a preoccupying thought.
The idea that public corporations have obligations that extend beyond the fiduciary responsibility to shareholders will be the dominant measure of responsible business behavior in the coming decade. Uncertainty about the extent of these commitments – commonly referenced as the environmental, social and governance (ESG) agenda – has produced equally variable responses from companies in the health care business.